This product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, in which the BBC3 gene (encoding the pro-apoptotic BH3-only protein PUMA) has been functionally disrupted. The polyclonal format comprises a heterogeneous mixture of cells harboring diverse editing events, generating a robust loss-of-function model without clonal selection and preserving population-level biological variation. This knockout tool is suitable for investigating p53-dependent apoptotic signaling and cancer cell death mechanisms in a genetically defined epithelial ovarian cancer background.
The parental A2780 cell line originates from an ovarian endometrioid adenocarcinoma and exhibits adherent epithelial morphology, serving as a widely utilized model for epithelial ovarian cancer research. A2780 cells retain functional p53 signaling and are extensively employed in studies of chemoresistance, apoptosis regulation, and drug sensitivity testing. Their well-characterized genetics and reproducible culture properties render them an ideal host for targeted gene disruption experiments focused on apoptosis pathways.
BBC3/PUMA is a critical BH3-only member of the BCL-2 family that functions as an essential mediator of p53-induced apoptosis. Following DNA damage, p53 transcriptionally upregulates BBC3, which then binds and neutralizes anti-apoptotic proteins including BCL-2, BCL-XL, and MCL-1. This antagonism relieves inhibition of BAX and BAK, permitting mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspase-9 via APAF-1, ultimately committing the cell to apoptosis. BBC3 is also regulated by additional transcription factors such as E2F1, FOXO3a, and p73, and its activity is modulated by glucocorticoid signaling. The protein interacts directly with BCL-2 family members and operates downstream of p53, forming a key node in the intrinsic apoptotic machinery.
In A2780 ovarian cancer cells, BBC3-mediated apoptosis is particularly relevant to understanding therapeutic responses and resistance mechanisms. Ovarian carcinomas frequently evade apoptosis, and loss of PUMA function can contribute to chemoresistance and tumor survival. This polyclonal knockout model allows dissection of BBC3-dependent apoptotic signaling, assessment of p53 pathway integrity, and interrogation of BCL-2 family interactions in an endometrioid adenocarcinoma background. Researchers can investigate how loss of PUMA influences sensitivity to DNA-damaging agents, BH3 mimetic drugs, or targeted therapies converging on the intrinsic apoptosis pathway.
Typical applications include western blotting for BBC3 ablation, RT-qPCR for transcriptional analysis, flow cytometry (Annexin V/PI) apoptosis assays, caspase-3/9 activity measurements, co-immunoprecipitation of BCL-2 complexes, and ChIP-qPCR for p53 promoter occupancy. Drug sensitivity profiling with chemotherapeutics or BH3 mimetics further enables translational oncology research. These knockout cells provide a versatile platform for dissecting p53-dependent cell death signaling and validating therapeutic targets in ovarian cancer. For technical specifications, validation data, and ordering information, please contact Ascent Research.
